New Oral PCSK9 Inhibitor: “MK-0616”

医学 耐受性 前蛋白转化酶 PCSK9 家族性高胆固醇血症 可欣 临床试验 他汀类 药代动力学 人口 不利影响 药理学 内科学 胆固醇 低密度脂蛋白受体 脂蛋白 环境卫生
作者
Zoya Siddiqui,William H. Frishman
出处
期刊:Cardiology in Review [Lippincott Williams & Wilkins]
被引量:3
标识
DOI:10.1097/crd.0000000000000655
摘要

MK-0616, a novel oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), represents a significant advancement in the treatment of hypercholesterolemia. Unlike current PCSK9 inhibitors, which are injectable monoclonal antibodies and siRNA molecules, MK-0616 offers a patient-friendly alternative. The development of MK-0616 involved innovative synthetic chemistry and in vitro mRNA display technology. This cutting-edge approach led to the creation of an orally administered peptide with the ability to cover a larger portion of PCSK9 compared to smaller, linear peptides. Phase 1 and 2b clinical trials have demonstrated MK-0616’s safety, efficacy, and pharmacokinetics. These trials indicate the drug’s dose-dependent systemic absorption and long half-life. Notably, MK-0616 has exhibited comparable low-density lipoprotein cholesterol-lowering effects to currently available PCSK9 inhibitors, all while maintaining good tolerability in diverse patient populations, including those concurrently on statin therapy. As MK-0616 advances to Phase 3 trials, its lipid-lowering potential for heterozygous familial hypercholesterolemia and its impact on reducing the time to adverse cardiac events will be evaluated in a broad and diverse population, including underrepresented groups. The results achieved so far are promising for individuals with hypercholesterolemia, as they offer a potential solution for effectively lowering low-density lipoprotein cholesterol in patients on statin therapy and mitigating the risk of cardiovascular events. Ongoing research and monitoring will be critical to establish its long-term safety and efficacy, but MK-0616 may emerge as a valuable addition to the array of lipid-lowering therapies available to patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
车轮滚滚发布了新的文献求助10
1秒前
1秒前
闫闫冰峰完成签到,获得积分10
2秒前
小白完成签到,获得积分10
2秒前
yuanyuan完成签到,获得积分10
2秒前
demoliu完成签到,获得积分10
2秒前
4秒前
平淡冬亦完成签到 ,获得积分10
5秒前
万能图书馆应助Yolen LI采纳,获得10
5秒前
Kayla完成签到,获得积分10
5秒前
WNL发布了新的文献求助10
6秒前
7秒前
7秒前
LZQ完成签到,获得积分0
7秒前
松19发布了新的文献求助30
9秒前
见花开完成签到,获得积分20
9秒前
愤怒的源智完成签到,获得积分10
10秒前
yuaner发布了新的文献求助10
11秒前
无心的若山完成签到,获得积分10
11秒前
13秒前
LUKUYU完成签到,获得积分10
13秒前
13秒前
研友_VZG7GZ应助肉片牛帅帅采纳,获得10
13秒前
13秒前
健壮的涑完成签到 ,获得积分10
15秒前
sikh发布了新的文献求助10
17秒前
Yolen LI发布了新的文献求助10
17秒前
科研通AI5应助ahhhhh采纳,获得10
17秒前
18秒前
18秒前
20秒前
乐鱼完成签到,获得积分10
21秒前
21秒前
梁其杰完成签到,获得积分10
21秒前
完美世界应助夜已深采纳,获得10
21秒前
科研通AI5应助Hbobo采纳,获得10
22秒前
精明蘑菇完成签到,获得积分10
23秒前
江上发布了新的文献求助10
23秒前
24秒前
高分求助中
Encyclopedia of Mathematical Physics 2nd edition 888
Technologies supporting mass customization of apparel: A pilot project 600
Hydropower Nation: Dams, Energy, and Political Changes in Twentieth-Century China 500
Introduction to Strong Mixing Conditions Volumes 1-3 500
Pharmacological profile of sulodexide 400
Optical and electric properties of monocrystalline synthetic diamond irradiated by neutrons 320
共融服務學習指南 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3805370
求助须知:如何正确求助?哪些是违规求助? 3350335
关于积分的说明 10348557
捐赠科研通 3066264
什么是DOI,文献DOI怎么找? 1683641
邀请新用户注册赠送积分活动 809105
科研通“疑难数据库(出版商)”最低求助积分说明 765243